益气温阳通痹法治疗糖尿病合并冠心病的临床观察及对Cys C的影响
|
摘要
1.研究背景
糖尿病合并冠心病的发病率不断增加,已成为糖尿病患者致死致残的主要原因,这不仅对患者的生活质量及生命构成严重的威胁,也给社会带来了巨大的经济压力。因其严重的临床表现以及与糖尿病患者死亡的高度相关性,已经成为当今医学界的研究热点。
国内外学者对糖尿病合并冠心病的研究十分重视,从不同角度、采用不同方法进行观察研究,但迄今为止,该病的病因病机尚未完全阐明,在其临床治疗方面仍以对症治疗为主。因此,探寻该病有效的防治方案已经成为当务之急。
中医药在治疗糖尿病及其并发症方面有悠久的历史和丰富的经验,特别是在辨证论治基础上的灵活处方用药是中医药的优势所在,因此,寻求糖尿病合并冠心病的中医药有效治疗方法显得尤为迫切。
2.研究目的
验证益气温阳通痹法(桂枝甘草汤合瓜蒌薤白半夏汤加减)治疗糖尿病合并冠心病的疗效及相关中医药优势,探讨糖尿病合并冠心病的中医病因病机及证治规律。通过治疗前后检测指标的客观变化情况,揭示其作用机理。旨在探索防治糖尿病合并冠心病的有效方药,从而为中医药治疗糖尿病合并冠心病提供新的思路与方法。
3.研究内容与方法
主要包括理论和文献研究及临床研究两个部分。
3.1理论和文献研究部分
该部分包括三个方面的内容。首先,回顾了近年来现代医学对糖尿病合并冠心病的研究进展,主要从糖尿病合并冠心病的流行病学研究、临床特点、发病机理、实验室检查、治疗等方面进行总结。其次,重点介绍了血清胱抑素C的生物学特性、测定方法及其与心血管疾病的关系。最后,着重介绍了糖尿病合并冠心病的中医药研究进展,包括中医病名的认识、病因病机、实验研究、辨证施治、中成药治疗、单味药研究等方面。
3.2临床研究部分
该部分观察了益气温阳通痹法治疗糖尿病合并冠心病的临床疗效,采用随机对照临床试验设计方法,纳入统计的合格受试对象有88例,其中治疗组45例,对照组43例。对照组给予包括教育心理调整、饮食控制、适当运动、控制血糖和对症处理等在内的基础治疗,治疗组在对照组的基础上,加用益气温阳通痹中药汤剂进行辨证分型治疗,中药每日1剂,水煎约200ml,分两次口服。两组均治疗观察8周。重点观察中医临床症状、血清胱抑素C、尿微量白蛋白、空腹血糖、餐后2小时血糖、糖化血红蛋白、血脂、心电图、超声心动图等指标。
4.结果
4.1两组临床总疗效的比较,治疗组显效11例,有效18例,无效16例,总有效率为64.4%,对照组显效9例,有效13例,无效21例,总有效率为51.1%,治疗组的总有效率高于对照组,但经统计学处理,差异无统计学意义(P＞0.05),还不能认为两组总疗效有差别,两组疗效相当。
4.2两组中医证候疗效的比较,治疗组临床痊愈5例,显效11例,有效25例,无效4例,总有效率为91.1%,对照组临床痊愈2例,显效8例,有效15例,无效18例,总有效率为58.1%,治疗组中医证候疗效优于对照组(P＜0.01)。
4.3两组患者中医症状积分的比较,与本组治疗前相比,两组治疗后症状积分下降有统计学意义(P＜0.01),可以认为两组治疗后的中医症状积分降低。两组治疗后症状积分下降差值相比较,差异有统计学意义(P＜0.01),可以认为两组不同治疗方法对中医症状积分的降低效果不同,治疗组降低效果较好。
4.4治疗组治疗前后的FPG值相比,差异有统计学意义(P＜0.01),对照组治疗前后的FPG值相比,差异无统计学意义(P＞0.05)。两组治疗后FPG下降差值的比较,差异有统计学意义(P＜0.01),可以认为两组不同的治疗方法对FPG的降低效果不同,治疗组降低FPG效果较好。
治疗组治疗前后的2hPG值相比,差异有统计学意义(P＜0.01),对照组治疗前后的2hPG值相比,差异无统计学意义(P＞0.05)。而两组治疗后2hPG下降差值的比较,差异有统计学意义(P＜0.05),可以认为两组不同治疗方法对2hPG的降低效果不同,治疗组降低2hPG效果较好。
两组治疗后的HbAlc均有所下降,可以认为两组治疗后的HbAlc降低(P＜0.05)。而两组治疗后HbAlc下降差值的比较,差异无统计学意义(P＞0.05),还不能认为两组不同的治疗方法对HbAlc的降低效果不同,两组疗效相当。
4.5两组治疗后的mALB值均有所下降,可以认为两组治疗后的mALB降低(P＜0.05)。而两组治疗后mALB下降差值的比较,差异无统计学意义(P＞0.05),还不能认为两组不同的治疗方法对mALB的降低效果不同。
4.6两组治疗后的Cys C值均有所下降,与本组治疗前相比,经统计学处理,P＜0.01,差异有统计学意义,可以认为两组治疗后的Cys C降低。而两组治疗后Cys C下降差值的比较,经统计学处理,P＜0.05,差异有统计学意义,可以认为两组不同的治疗方法对Cys C的降低效果不同,治疗组降低Cys C效果较好。
4.7两组治疗后的CHOL、TG、LDL-C水平有所下降,而HDL-C水平则有上升趋势。与本组治疗前相比,差异有统计学意义(P＜0.05),可以认为两组在治疗之后的CHOL、TG、LDL-C值降低,HDL-C值升高。两组治疗前后CHOL、HDL-C差值的比较,差异无统计学意义(P＞0.05),还不能认为两组不同的治疗方法对CHOL的降低、HDL-C的升高效果有所不同。而治疗后TG、LDL-C的组间比较,差异有统计学意义(P＜0.05),可以认为两组不同的治疗方法对TG、LDL-C的降低效果不同,治疗组降低效果较好。
4.8两组心电图疗效的比较,治疗组心电图显效16例,有效19例,无效10例,总有效率为77.8%,对照组显效10例,有效14例,无效19例,总有效率为55.8%,治疗组心电图疗效优于对照组(P＜0.05)。
4.9两组在治疗期间均未发生不良反应,治疗前后的血分析(WBC、HGB、RBC、PLT)、肝功能(ALT、AST)、肾功能(BUN、CREA)的比较,差异无统计学意义(P＞0.05)。
5.结论
5.1糖尿病合并冠心病相当于中医学“消渴”、“胸痹心痛”等范畴,可称为“消渴病心病”,其病因是消渴病迁延不愈、日久生变而成,其发病与年老体虚、劳倦内伤、饮食不节、情志失调、久病不愈等因素有关。其病位在心,与肺、脾、肝、肾密切相关。病性属本虚标实、虚实夹杂。
5.2气阴两虚是糖尿病合并冠心病的发病基础,在此基础上,演变为气血阴阳的亏虚,其中,心气虚、心阳虚是糖尿病合并冠心病的病机关键,脾肾亏虚是糖尿病合并冠心病的中心环节,痰浊、血瘀贯穿糖尿病合并冠心病的始终。
5.3治疗上应标本兼顾,扶正祛邪。本虚宜补,应权衡气血阴阳之不足,调阴阳补气血,调整脏腑之偏衰,尤应重视补益心气、温通心阳。标实宜泻,针对气滞、血瘀、寒凝、痰浊而理气、活血、温通、化痰,尤重活血通络治法。特别强调益气温阳通痹的治疗方法。
5.4临床研究证实了益气温阳通痹法可明显缓解糖尿病合并冠心病患者胸闷胸痛等临床症状,提高患者生活质量,能够降低空腹血糖及餐后2小时血糖,改善心肌缺血状态,能够纠正脂代谢紊乱,降低血清胱抑素C水平。
5.5其作用机制可能与调节糖代谢、纠正脂代谢紊乱、改善心肌缺血、保护心肾功能等有关。
5.6治疗组可以降低血清Cys C水平,鉴于血清Cys C在一定程度上能够反映冠心病患者的病情程度及心脏功能,对冠心病患者将来继发心血管事件及在其死亡率方面有独立的预测价值,血清Cys C的检测可作为动态观察指标,它的测定能够为临床医生提供参考,提醒临床医生及时选择更加合适的治疗方法,具有临床实用价值。
血清Cys C与糖尿病合并冠心病的关系还需要更深入的研究,其作用机制有待于进一步探讨。临床上,应结合其它指标综合分析,从而对糖尿病合并冠心病的发展、预后做出客观评价。
5.7研究过程中,未发现任何不良反应,临床使用安全。
本研究初步显示出中医药在缓解临床症状、提高生活质量、改善实验室检测指标等方面有较大的优势。益气温阳通痹法治疗糖尿病合并冠心病,切中病机,临床疗效确切,安全性好,值得进一步推广。
1 Background
With the incidence of DM with CHD increased,it has become the main reason for disability or death in diabetic patients;it will not only affect the quality of life for patients and pose a serious threat to life,but also create an enormous financial burden for the society.Prevention and treatment of DM with CHD has become the focus of research in recent years.
Domestic and foreign scholars attach great importance to this problem and have carried out a number of studies on DM with CHD.So far,however,the pathogeny has not yet been fully clarified;its clinical treatment is still mainly symptomatic treatment.Therefore,the search for effective disease control programs has become a top priority.
TCM in the treatment of diabetes and its complications have a long history and rich experience,especially in the treatment of flexibility based on the prescription medication is the advantages of TCM,Therefore,the search for DM with CHD in Chinese medicine effective treatment methods will become more necessary.
2 Objectives
The objectives of this clinical observation are to judge the curative effect of Replenishing Qi,Warming Yang,Resolving Stagnation Therapy(Ramuli Cinnamomi and Glycyrrhizae Decoction combined Gualou Xiebai Decoction) on DM with CHD according to the curative standard and verify the advantages of TCM; to explore its etiology and pathogenesis and probe into treatment of the law; to reveal its mechanism according to the changes of clinical symptoms and laboratory indexes before and after treatment;to search for the effective prescriptions and provide new ideas and methods for the prevention and treatment of DM with CHD.
3 Contents and methods of study
This paper consists of two parts,which are summaries of documents and a clinical observation.
3.1 Theoretical and document research
Theoretical and document research includes the three parts.First of all, we review the modern medicine studies on DM with CHD in recent years,including epidemiological study,clinical manifestation,etiopathogenesis,laboratory examination and treatment,etc.Secondly,we focus on the biological characteristics of serum cystatin C,its determination and the relationship between Cys C and cardiovascular disease.Finally,introduce the traditional Chinese medical research progress about MD with CHD,including awareness of the Names of Disease,etiology and pathogenesis,experimental research, treatment based on syndrome differentiation,Chinese formulated products treatment,single drug research.
3.2 Clinical observation
The clinical study observes the clinical effect of Replenishing Qi, Warming Yang,and Resolving Stagnation Therapy on treating DM with CHD.88 patients conforming to the diagnostic criterion were randomly divided into two groups,which are treatment group(45 patients) and control group(43 patients).Education and psychological adjustment,alimentary control,proper exercise,control blood glucose and symptomatic therapy were given to the control group,on the basis of suitable remedy,Chinese medicine was applied in the treatment group,which has the function of Replenishing Qi,Warming Yang,Resolving Stagnation.Take a dose twice a day.Two groups were treated for 8 weeks.The clinical symptoms,serum cystatin C,mALB,FPG,2hPG, glycosylated hemoglobin,blood lipid,electrocardiogram and ultrasonic cardiogram were observed.
4 Results
4.1 The result of clinical comprehensive efficacy:In treatment group, among the 45 cases,11 cases were markedly effective,18 cases were effective and 16 cases were ineffective,the total effective rate was 64.4%.As for the control group,among the 43 cases,9 cases were markedly effective,13 cases were effective and 21 cases were ineffective,the total effective rate was 51.1%.The total effective rate in treatment group is higher than in control group.By statistics,no-significant difference was revealed(P＞0.05).
4.2 The result of Chinese medicine syndromes:In treatment group,among the 45 cases,5 cases were cured,11 cases were markedly effective,25 cases were effective and 4 cases were ineffective,the total effective rate was 91.1%.As for the control group,among the 43 cases,2 caseswerecured,8cases were markedly effective,15 cases were effective and 18 cases were ineffective, the total effective rate was 58.1%.The treatment group was superior to the control group in Chinese medicine syndromes efficacy(P＜0.01).
4.3 Scores of syndrome of TCM:Compaired with pre-post treatment,scores of syndrome of TCM descented obviously(P＜0.01).It is clear that the scores of syndrome of TCM in treatment group and control group after treatment were significantly lower than that before treatment.Comparing the scores of syndrome of TCM between the two groups,there was significant difference between treatment group and control group(P＜0.01).
4.4 Compaired with pre-post treatment,fasting plasma glucose descented in treatment group(P＜0.01).There was no significant difference in control troup before and after treatment(P＞0.05).Comparing the level of FPG between the two groups,there was significant difference(P＜0.01).The treatment group was superior to the control group in decreasing FPG.
Compaired with pre-post treatment,two-hour postprandial plasma glucose descented in treatment group(P＜0.01).There was no significant difference in control troup before and after treatment(P＞0.05).Comparing the level of 2hPGbetweenthe two groups,there was significant difference(P＜0.05). The treatment group was superior to the control group in decreasing 2hPG.
After treatment HbAlc was decreased in treatment group and control group. Compaired with pre-post treatment,the difference was statistically significant(P＜0.05).Comparing the level of HbAlc between the two groups, there was no significant difference(P＞0.05).
4.5 After treatment mALB was decreased in treatment group and control group. Compaired with pre-post treatment,the difference was statistically significant(P＜0.05).Comparing the level of mALBbetweenthe two groups, there was no significant difference(P＞0.05).
4.6 After treatment serum Cys C was decreased in treatment group and control group.Compaired with pre-post treatment,the difference was statistically significant(P＜0.01).Comparing the level of serum Cys C between the two groups,there was significant difference(P＜0.05).The treatment group was superior to the control group in decreasing serum Cys C.
4.7 After treatment CHOL,TG and LDL-C were decreased in treatment group and control group.At the same time,HDL-C was increased.Compaired with pre-post treatment,the difference was statistically significant(P＜0.05). Comparing the levels of CHOL and HDL-C between the two groups,there were no significant differences(P＞0.05).Comparing the levels of TG and LDL-C between the two groups,there were significant differences(P＜0.05).The treatment group was superior to the control group in decreasing TG and LDL-C.
4.8 The result of electrocardiogram efficiencies:In treatment group, among the 45 cases,16 cases were markedly effective,19 cases were effective and 10 cases were ineffective,the total effective rate was 77.8%.As for the control group,among the 43 cases,10 cases were markedly effective,14 cases were effective and 19 cases were ineffective,the total effective rate was 55.8%.The treatment group was superior to the control group in electrocardiogram efficiencies(P＜0.05).
4.9 During treatment the two groups had no obvious side effects.Compaired with pre-post treatment,there were no significant differences in hemanalysis, hepatic funtion or renal function(P＞0.05).
5 Conclusions
5.1DM with CHD is nearly equivalent to "wasting-thirst" and "chest pain" according to TCM term,which can be referred to as the "Heart of Diabetes" It always changes from a long period of time.Some factors are relevant to the development of DM with CHD,such as old age and weakness, overstrain and internal injuries,improper diet,emotional maladjustment, obstinate disease,etc.Its disease-bit heart,lung,spleen,liver and kidney are closely related,which is syndrome of deficiency Ben and excessive Biao, deficiency and excess interlace each other.
5.2 Qi and Yin Deficiency is the foundation of DM with CHD which makes deficiency of yin,yang,qi,blood.Among these,asthenia of heart qi and yang is the the key of pathogenesis,deficiency of spleen and kidney is central segment,phlegm turbidity and blood-stasis are present during the through course.
5.3 We should strengthen body resistance to dispel pathogenic factors, be weighed against the lack of qi blood yin and yang,adjusting the partial failure of internal organs,especially paying attention to replenishing heart Qi and Wen Tong Xin Yang.At the same time,we should regulate Qi,activate the blood,Wen Tong and dissolve phlegm flexibly according to the actual situation,especially activating blood circulation and dredging the collaterals.In a word,Replenishing Qi,Warming Yang,Resolving Stagnation Therapy was emphasizing in particular.
5.4 This clinical observation confirms that Replenishing Qi,Warming Yang, Resolving Stagnation Therapy can significantly alleviate the patients' clinical symptoms such as chest tightness,chest pain,etc.It can improve quality of life,reduce FPG and 2hPG,improve the state of myocardial ischemia, correct the disorders of lipid metabolism and reduce serum cystatin C.
5.5 Its mechanism may be correlated with the regulation of glucose metabolism,correct the disorders of lipid metabolism,improve the state of myocardial ischemia and protect cardiac and renal function.
5.6 The results show that the treatment group can reduce the level of serum Cys C.Dynamic detection of serum Cys C can be an index,the level of serum Cys C can provide reference for clinical medication because it can reflect the severity of CHD to a certain extent,it is an important predictor for secondary cardiovascular events and the risk of death among patients with known CHD.
The relationship between Serum Cys C and DM with CHD also need more in-depth research,its mechanism remains to be further explored.Clinically,Cys C should be combined with other indicators of a comprehensive analysis,in order to make an objective assessment of development and prognosis of DM with CHD.
5.7 During the course of the study,we have not found any adverse reactions.We think that this traditional Chinese medicine is safe and sure.
This preliminary observation shows that traditional Chinese medicine has the following advantages,such as alleviate clinical symptoms,improve quality of life and amelioration clinic laboratory tests.Replenishing Qi,Warming Yang,Resolving Stagnation Therapy used in treating DM with CHD has the exact clinical efficacy,which is safety and hit the pathogenesis.So it is worthy of spreading.
糖尿病合并冠心病的发病率不断增加,已成为糖尿病患者致死致残的主要原因,这不仅对患者的生活质量及生命构成严重的威胁,也给社会带来了巨大的经济压力。因其严重的临床表现以及与糖尿病患者死亡的高度相关性,已经成为当今医学界的研究热点。
国内外学者对糖尿病合并冠心病的研究十分重视,从不同角度、采用不同方法进行观察研究,但迄今为止,该病的病因病机尚未完全阐明,在其临床治疗方面仍以对症治疗为主。因此,探寻该病有效的防治方案已经成为当务之急。
中医药在治疗糖尿病及其并发症方面有悠久的历史和丰富的经验,特别是在辨证论治基础上的灵活处方用药是中医药的优势所在,因此,寻求糖尿病合并冠心病的中医药有效治疗方法显得尤为迫切。
2.研究目的
验证益气温阳通痹法(桂枝甘草汤合瓜蒌薤白半夏汤加减)治疗糖尿病合并冠心病的疗效及相关中医药优势,探讨糖尿病合并冠心病的中医病因病机及证治规律。通过治疗前后检测指标的客观变化情况,揭示其作用机理。旨在探索防治糖尿病合并冠心病的有效方药,从而为中医药治疗糖尿病合并冠心病提供新的思路与方法。
3.研究内容与方法
主要包括理论和文献研究及临床研究两个部分。
3.1理论和文献研究部分
该部分包括三个方面的内容。首先,回顾了近年来现代医学对糖尿病合并冠心病的研究进展,主要从糖尿病合并冠心病的流行病学研究、临床特点、发病机理、实验室检查、治疗等方面进行总结。其次,重点介绍了血清胱抑素C的生物学特性、测定方法及其与心血管疾病的关系。最后,着重介绍了糖尿病合并冠心病的中医药研究进展,包括中医病名的认识、病因病机、实验研究、辨证施治、中成药治疗、单味药研究等方面。
3.2临床研究部分
该部分观察了益气温阳通痹法治疗糖尿病合并冠心病的临床疗效,采用随机对照临床试验设计方法,纳入统计的合格受试对象有88例,其中治疗组45例,对照组43例。对照组给予包括教育心理调整、饮食控制、适当运动、控制血糖和对症处理等在内的基础治疗,治疗组在对照组的基础上,加用益气温阳通痹中药汤剂进行辨证分型治疗,中药每日1剂,水煎约200ml,分两次口服。两组均治疗观察8周。重点观察中医临床症状、血清胱抑素C、尿微量白蛋白、空腹血糖、餐后2小时血糖、糖化血红蛋白、血脂、心电图、超声心动图等指标。
4.结果
4.1两组临床总疗效的比较,治疗组显效11例,有效18例,无效16例,总有效率为64.4%,对照组显效9例,有效13例,无效21例,总有效率为51.1%,治疗组的总有效率高于对照组,但经统计学处理,差异无统计学意义(P＞0.05),还不能认为两组总疗效有差别,两组疗效相当。
4.2两组中医证候疗效的比较,治疗组临床痊愈5例,显效11例,有效25例,无效4例,总有效率为91.1%,对照组临床痊愈2例,显效8例,有效15例,无效18例,总有效率为58.1%,治疗组中医证候疗效优于对照组(P＜0.01)。
4.3两组患者中医症状积分的比较,与本组治疗前相比,两组治疗后症状积分下降有统计学意义(P＜0.01),可以认为两组治疗后的中医症状积分降低。两组治疗后症状积分下降差值相比较,差异有统计学意义(P＜0.01),可以认为两组不同治疗方法对中医症状积分的降低效果不同,治疗组降低效果较好。
4.4治疗组治疗前后的FPG值相比,差异有统计学意义(P＜0.01),对照组治疗前后的FPG值相比,差异无统计学意义(P＞0.05)。两组治疗后FPG下降差值的比较,差异有统计学意义(P＜0.01),可以认为两组不同的治疗方法对FPG的降低效果不同,治疗组降低FPG效果较好。
治疗组治疗前后的2hPG值相比,差异有统计学意义(P＜0.01),对照组治疗前后的2hPG值相比,差异无统计学意义(P＞0.05)。而两组治疗后2hPG下降差值的比较,差异有统计学意义(P＜0.05),可以认为两组不同治疗方法对2hPG的降低效果不同,治疗组降低2hPG效果较好。
两组治疗后的HbAlc均有所下降,可以认为两组治疗后的HbAlc降低(P＜0.05)。而两组治疗后HbAlc下降差值的比较,差异无统计学意义(P＞0.05),还不能认为两组不同的治疗方法对HbAlc的降低效果不同,两组疗效相当。
4.5两组治疗后的mALB值均有所下降,可以认为两组治疗后的mALB降低(P＜0.05)。而两组治疗后mALB下降差值的比较,差异无统计学意义(P＞0.05),还不能认为两组不同的治疗方法对mALB的降低效果不同。
4.6两组治疗后的Cys C值均有所下降,与本组治疗前相比,经统计学处理,P＜0.01,差异有统计学意义,可以认为两组治疗后的Cys C降低。而两组治疗后Cys C下降差值的比较,经统计学处理,P＜0.05,差异有统计学意义,可以认为两组不同的治疗方法对Cys C的降低效果不同,治疗组降低Cys C效果较好。
4.7两组治疗后的CHOL、TG、LDL-C水平有所下降,而HDL-C水平则有上升趋势。与本组治疗前相比,差异有统计学意义(P＜0.05),可以认为两组在治疗之后的CHOL、TG、LDL-C值降低,HDL-C值升高。两组治疗前后CHOL、HDL-C差值的比较,差异无统计学意义(P＞0.05),还不能认为两组不同的治疗方法对CHOL的降低、HDL-C的升高效果有所不同。而治疗后TG、LDL-C的组间比较,差异有统计学意义(P＜0.05),可以认为两组不同的治疗方法对TG、LDL-C的降低效果不同,治疗组降低效果较好。
4.8两组心电图疗效的比较,治疗组心电图显效16例,有效19例,无效10例,总有效率为77.8%,对照组显效10例,有效14例,无效19例,总有效率为55.8%,治疗组心电图疗效优于对照组(P＜0.05)。
4.9两组在治疗期间均未发生不良反应,治疗前后的血分析(WBC、HGB、RBC、PLT)、肝功能(ALT、AST)、肾功能(BUN、CREA)的比较,差异无统计学意义(P＞0.05)。
5.结论
5.1糖尿病合并冠心病相当于中医学“消渴”、“胸痹心痛”等范畴,可称为“消渴病心病”,其病因是消渴病迁延不愈、日久生变而成,其发病与年老体虚、劳倦内伤、饮食不节、情志失调、久病不愈等因素有关。其病位在心,与肺、脾、肝、肾密切相关。病性属本虚标实、虚实夹杂。
5.2气阴两虚是糖尿病合并冠心病的发病基础,在此基础上,演变为气血阴阳的亏虚,其中,心气虚、心阳虚是糖尿病合并冠心病的病机关键,脾肾亏虚是糖尿病合并冠心病的中心环节,痰浊、血瘀贯穿糖尿病合并冠心病的始终。
5.3治疗上应标本兼顾,扶正祛邪。本虚宜补,应权衡气血阴阳之不足,调阴阳补气血,调整脏腑之偏衰,尤应重视补益心气、温通心阳。标实宜泻,针对气滞、血瘀、寒凝、痰浊而理气、活血、温通、化痰,尤重活血通络治法。特别强调益气温阳通痹的治疗方法。
5.4临床研究证实了益气温阳通痹法可明显缓解糖尿病合并冠心病患者胸闷胸痛等临床症状,提高患者生活质量,能够降低空腹血糖及餐后2小时血糖,改善心肌缺血状态,能够纠正脂代谢紊乱,降低血清胱抑素C水平。
5.5其作用机制可能与调节糖代谢、纠正脂代谢紊乱、改善心肌缺血、保护心肾功能等有关。
5.6治疗组可以降低血清Cys C水平,鉴于血清Cys C在一定程度上能够反映冠心病患者的病情程度及心脏功能,对冠心病患者将来继发心血管事件及在其死亡率方面有独立的预测价值,血清Cys C的检测可作为动态观察指标,它的测定能够为临床医生提供参考,提醒临床医生及时选择更加合适的治疗方法,具有临床实用价值。
血清Cys C与糖尿病合并冠心病的关系还需要更深入的研究,其作用机制有待于进一步探讨。临床上,应结合其它指标综合分析,从而对糖尿病合并冠心病的发展、预后做出客观评价。
5.7研究过程中,未发现任何不良反应,临床使用安全。
本研究初步显示出中医药在缓解临床症状、提高生活质量、改善实验室检测指标等方面有较大的优势。益气温阳通痹法治疗糖尿病合并冠心病,切中病机,临床疗效确切,安全性好,值得进一步推广。
1 Background
With the incidence of DM with CHD increased,it has become the main reason for disability or death in diabetic patients;it will not only affect the quality of life for patients and pose a serious threat to life,but also create an enormous financial burden for the society.Prevention and treatment of DM with CHD has become the focus of research in recent years.
Domestic and foreign scholars attach great importance to this problem and have carried out a number of studies on DM with CHD.So far,however,the pathogeny has not yet been fully clarified;its clinical treatment is still mainly symptomatic treatment.Therefore,the search for effective disease control programs has become a top priority.
TCM in the treatment of diabetes and its complications have a long history and rich experience,especially in the treatment of flexibility based on the prescription medication is the advantages of TCM,Therefore,the search for DM with CHD in Chinese medicine effective treatment methods will become more necessary.
2 Objectives
The objectives of this clinical observation are to judge the curative effect of Replenishing Qi,Warming Yang,Resolving Stagnation Therapy(Ramuli Cinnamomi and Glycyrrhizae Decoction combined Gualou Xiebai Decoction) on DM with CHD according to the curative standard and verify the advantages of TCM; to explore its etiology and pathogenesis and probe into treatment of the law; to reveal its mechanism according to the changes of clinical symptoms and laboratory indexes before and after treatment;to search for the effective prescriptions and provide new ideas and methods for the prevention and treatment of DM with CHD.
3 Contents and methods of study
This paper consists of two parts,which are summaries of documents and a clinical observation.
3.1 Theoretical and document research
Theoretical and document research includes the three parts.First of all, we review the modern medicine studies on DM with CHD in recent years,including epidemiological study,clinical manifestation,etiopathogenesis,laboratory examination and treatment,etc.Secondly,we focus on the biological characteristics of serum cystatin C,its determination and the relationship between Cys C and cardiovascular disease.Finally,introduce the traditional Chinese medical research progress about MD with CHD,including awareness of the Names of Disease,etiology and pathogenesis,experimental research, treatment based on syndrome differentiation,Chinese formulated products treatment,single drug research.
3.2 Clinical observation
The clinical study observes the clinical effect of Replenishing Qi, Warming Yang,and Resolving Stagnation Therapy on treating DM with CHD.88 patients conforming to the diagnostic criterion were randomly divided into two groups,which are treatment group(45 patients) and control group(43 patients).Education and psychological adjustment,alimentary control,proper exercise,control blood glucose and symptomatic therapy were given to the control group,on the basis of suitable remedy,Chinese medicine was applied in the treatment group,which has the function of Replenishing Qi,Warming Yang,Resolving Stagnation.Take a dose twice a day.Two groups were treated for 8 weeks.The clinical symptoms,serum cystatin C,mALB,FPG,2hPG, glycosylated hemoglobin,blood lipid,electrocardiogram and ultrasonic cardiogram were observed.
4 Results
4.1 The result of clinical comprehensive efficacy:In treatment group, among the 45 cases,11 cases were markedly effective,18 cases were effective and 16 cases were ineffective,the total effective rate was 64.4%.As for the control group,among the 43 cases,9 cases were markedly effective,13 cases were effective and 21 cases were ineffective,the total effective rate was 51.1%.The total effective rate in treatment group is higher than in control group.By statistics,no-significant difference was revealed(P＞0.05).
4.2 The result of Chinese medicine syndromes:In treatment group,among the 45 cases,5 cases were cured,11 cases were markedly effective,25 cases were effective and 4 cases were ineffective,the total effective rate was 91.1%.As for the control group,among the 43 cases,2 caseswerecured,8cases were markedly effective,15 cases were effective and 18 cases were ineffective, the total effective rate was 58.1%.The treatment group was superior to the control group in Chinese medicine syndromes efficacy(P＜0.01).
4.3 Scores of syndrome of TCM:Compaired with pre-post treatment,scores of syndrome of TCM descented obviously(P＜0.01).It is clear that the scores of syndrome of TCM in treatment group and control group after treatment were significantly lower than that before treatment.Comparing the scores of syndrome of TCM between the two groups,there was significant difference between treatment group and control group(P＜0.01).
4.4 Compaired with pre-post treatment,fasting plasma glucose descented in treatment group(P＜0.01).There was no significant difference in control troup before and after treatment(P＞0.05).Comparing the level of FPG between the two groups,there was significant difference(P＜0.01).The treatment group was superior to the control group in decreasing FPG.
Compaired with pre-post treatment,two-hour postprandial plasma glucose descented in treatment group(P＜0.01).There was no significant difference in control troup before and after treatment(P＞0.05).Comparing the level of 2hPGbetweenthe two groups,there was significant difference(P＜0.05). The treatment group was superior to the control group in decreasing 2hPG.
After treatment HbAlc was decreased in treatment group and control group. Compaired with pre-post treatment,the difference was statistically significant(P＜0.05).Comparing the level of HbAlc between the two groups, there was no significant difference(P＞0.05).
4.5 After treatment mALB was decreased in treatment group and control group. Compaired with pre-post treatment,the difference was statistically significant(P＜0.05).Comparing the level of mALBbetweenthe two groups, there was no significant difference(P＞0.05).
4.6 After treatment serum Cys C was decreased in treatment group and control group.Compaired with pre-post treatment,the difference was statistically significant(P＜0.01).Comparing the level of serum Cys C between the two groups,there was significant difference(P＜0.05).The treatment group was superior to the control group in decreasing serum Cys C.
4.7 After treatment CHOL,TG and LDL-C were decreased in treatment group and control group.At the same time,HDL-C was increased.Compaired with pre-post treatment,the difference was statistically significant(P＜0.05). Comparing the levels of CHOL and HDL-C between the two groups,there were no significant differences(P＞0.05).Comparing the levels of TG and LDL-C between the two groups,there were significant differences(P＜0.05).The treatment group was superior to the control group in decreasing TG and LDL-C.
4.8 The result of electrocardiogram efficiencies:In treatment group, among the 45 cases,16 cases were markedly effective,19 cases were effective and 10 cases were ineffective,the total effective rate was 77.8%.As for the control group,among the 43 cases,10 cases were markedly effective,14 cases were effective and 19 cases were ineffective,the total effective rate was 55.8%.The treatment group was superior to the control group in electrocardiogram efficiencies(P＜0.05).
4.9 During treatment the two groups had no obvious side effects.Compaired with pre-post treatment,there were no significant differences in hemanalysis, hepatic funtion or renal function(P＞0.05).
5 Conclusions
5.1DM with CHD is nearly equivalent to "wasting-thirst" and "chest pain" according to TCM term,which can be referred to as the "Heart of Diabetes" It always changes from a long period of time.Some factors are relevant to the development of DM with CHD,such as old age and weakness, overstrain and internal injuries,improper diet,emotional maladjustment, obstinate disease,etc.Its disease-bit heart,lung,spleen,liver and kidney are closely related,which is syndrome of deficiency Ben and excessive Biao, deficiency and excess interlace each other.
5.2 Qi and Yin Deficiency is the foundation of DM with CHD which makes deficiency of yin,yang,qi,blood.Among these,asthenia of heart qi and yang is the the key of pathogenesis,deficiency of spleen and kidney is central segment,phlegm turbidity and blood-stasis are present during the through course.
5.3 We should strengthen body resistance to dispel pathogenic factors, be weighed against the lack of qi blood yin and yang,adjusting the partial failure of internal organs,especially paying attention to replenishing heart Qi and Wen Tong Xin Yang.At the same time,we should regulate Qi,activate the blood,Wen Tong and dissolve phlegm flexibly according to the actual situation,especially activating blood circulation and dredging the collaterals.In a word,Replenishing Qi,Warming Yang,Resolving Stagnation Therapy was emphasizing in particular.
5.4 This clinical observation confirms that Replenishing Qi,Warming Yang, Resolving Stagnation Therapy can significantly alleviate the patients' clinical symptoms such as chest tightness,chest pain,etc.It can improve quality of life,reduce FPG and 2hPG,improve the state of myocardial ischemia, correct the disorders of lipid metabolism and reduce serum cystatin C.
5.5 Its mechanism may be correlated with the regulation of glucose metabolism,correct the disorders of lipid metabolism,improve the state of myocardial ischemia and protect cardiac and renal function.
5.6 The results show that the treatment group can reduce the level of serum Cys C.Dynamic detection of serum Cys C can be an index,the level of serum Cys C can provide reference for clinical medication because it can reflect the severity of CHD to a certain extent,it is an important predictor for secondary cardiovascular events and the risk of death among patients with known CHD.
The relationship between Serum Cys C and DM with CHD also need more in-depth research,its mechanism remains to be further explored.Clinically,Cys C should be combined with other indicators of a comprehensive analysis,in order to make an objective assessment of development and prognosis of DM with CHD.
5.7 During the course of the study,we have not found any adverse reactions.We think that this traditional Chinese medicine is safe and sure.
This preliminary observation shows that traditional Chinese medicine has the following advantages,such as alleviate clinical symptoms,improve quality of life and amelioration clinic laboratory tests.Replenishing Qi,Warming Yang,Resolving Stagnation Therapy used in treating DM with CHD has the exact clinical efficacy,which is safety and hit the pathogenesis.So it is worthy of spreading.
引文
[1]吕卓人,姜馨.糖尿病与心血管危险控制[J].中华心血管病杂志,2001,29(10):637-639.
[2]胡绍文,郭瑞林,童光焕,等.实用糖尿病学(第2版)[M].北京:人民军医出版社.2003,304.
[3]何宇梅,郭庆畲,苏苹.2型糖尿病与心血管病危险的关系[J].医学综述,2001,7(6):354-355.
[4]徐成斌.糖尿病与心血管并发症[J].当代医学,2001,7(2):45-48.
[5]刘新民,张锦.实用内分泌疾病诊疗手册[M].北京:人民军医出版社.2008,575.
[6]钱薇薇,董砚虎.糖尿病并心血管病变的诊治进展[J].山东医药,2000,40(5):38-38.
[7]肖新华.糖尿病与心血管病[J].中国中西医结合杂志,2007,27(8):678-679.
[8]陈灏珠.实用内科学·第12版[M].北京:人民卫生出版社.2006,1028.
[9]单文华.糖尿病冠心病的临床特征[J].家庭医学,2006,(1):42-43.
[10]李勇,赖晓阳.2型糖尿病合并冠心病冠脉造影特点和支架植入治疗进展[J].实用临床医学(江西),2008,9(3):136-138.
[11]陶凯忠.高血糖与糖尿病血管病变及机制[J].中国糖尿病杂志,2001,9(5):306-308.
[12]曹国良,乔永芳.2型糖尿病餐后高血糖与心血管危险[J].医学与哲学,2004,25(11):43-44,57.
[13]傅一明.胰岛素抵抗的研究新进展[J].新医学,1999,30(12):733-734.
[14]祝之明.洞察胰岛素抵抗与糖尿病相关心血管危险因素[J].中华医学信息导报,2006,21(7):21.
[15]沈利亚.胰岛素抵抗与心血管疾病[J].江汉大学学报:自然科学版,2003,31(3):70-73.
[16]无.消除胰岛素抵抗--降低糖尿病心血管病变的关键[J].糖尿病之友,2003,
2(4):71-71.
[17]陈莉明.糖尿病心血管病变的研究现状[J].国外医学:内分泌学分册,2003,23(1):59-61.
[18]侯迎会,马立侠.他汀类药对糖尿病合并冠状动脉粥样硬化性心脏病的作用[J].中国热带医学,2005,5(2):310-311.
[19]何文姬,卜建宏,高书荣,等.2型糖尿病并发冠心病危险因素分析[J].医学综述,2007,13(7):536-537.
[20]胡量子,杨波,宋艳红.2型糖尿病伴冠心病患者超敏C反应蛋白的观察[J].临床心血管病杂志,2007,23(10):795-796.
[21]郭丽君.2型糖尿病伴冠心病C反应蛋白和尿酸变化的临床观察[J].实用医技杂志,2008,15(24):3262-3263.
[22]陈莉明.糖尿病心血管病变的研究现状[J].国外医学:内分泌学分册,2003,23(1):59-61.
[23]周英,李方雄.糖尿病合并冠心病患者血浆hs-CRP和尿酸水平的变化及临床意义[J].疑难病杂志,2008,7(1):8-10.
[24]徐懿,李月华.糖尿病合并冠状动脉粥样硬化性心脏病的发病及其相关特征[J].中国临床康复,2006,10(20):130-132.
[25]张晓梅,王正梅.尿微量白蛋白检测对Ⅱ型糖尿病合并冠心病患者的临床意义[J].中国医药指南,2006,11:56-57.
[26]陈伯良.尿微量白蛋白测定在糖尿病肾病及冠心病诊断中的应用[J].中国热带医学,2006,6(5):803.
[27]陈新华,高向玲.75例糖尿病合并冠心病患者尿微量白蛋白检测分析[J].山东医药,2006,46(17):56-57.
[28]田晓艳,秦艳华.2型糖尿病患者微量白蛋白尿与糖尿病性心脏病临床分析[J].中国当代医学,2007,6(12):32-33.
[29]刘芳,张新书,王佑民,等.QTVI对2型糖尿病患者微量白蛋白尿与左心收缩功能的相关性研究[J].安徽医科大学学报,2007,42(1):73-75.
[30]张晓野,郭战利,左岩霞,等.尿微量白蛋白水平与糖尿病合并冠心病患者心功能的相关性分析[J].山东医药,2008,48(2):51-52.
[31]陈立东,杨文东.糖尿病患者尿微量白蛋白与冠心病的关系[J].山西医科大学学报,2006,37(6):625-627.
[32]郑法雷,章友康.肾脏病临床与进展[M].北京:人民军医出版社,2005,11.
[33]韦秀英.2型糖尿病病人微量白蛋白尿的危险因素分析[J].右江民族医学院学报,2004,3:333-335.
[34]郭凡.2型糖尿病患者微量白蛋白尿与缺血性心脏病的相关分析[J].辽宁医学杂志,2006,20(2):81-82.
[35]宁静(综述),陈军(审校).同型半胱氨酸--心血管疾病新的重要检测指标[J].国际检验医学杂志,2007,28(4):369-369,372.
[36]周灵丽,卢纹凯.2型糖尿病患者血浆总同型半胱氨酸水平与大血管病变的关系[J].中国糖尿病杂志,2003,11(4):265-267.
[37]吴乃君,陈冬,金秀平,等.2型糖尿病患者血清同型半胱氨酸检测的临床意义 [J].山东医药,2006,46(34):51-52.
[38]李刚,周兴文.新的冠心病危险因素[J].心血管病学进展,2005,26(3):266-271.
[39]陈军政.2型糖尿病肾病患者血清胱抑素C的检测及意义[J].微循环学杂志,2007,17(3):58-59.
[40]苏彩芳,高岩.血清胱抑素C测定临床意义探讨[J].中国病案,2006,7(6):47-48.
[41]黄君富.血清胱抑素C测定的临床意义及方法学进展[J].国外医学:临床生物化学与检验学分册,1999,20(1):8-10.
[42]徐志强(综述),王骏,王鸣和(审校).胱抑素C与冠心病相关性的研究进展[J].心血管病学进展,2008,29(1):64-67.
[43]陈治奎,葛长江,胡申江.胱抑素C与心血管疾病的关系[J].生理科学进展,2003,34(3):269-271.
[44]任爱英,王凡.血清胱抑素C的临床应用及研究[J].检验医学与临床,2008,(1):32-34.
[45]Quehenberger P,Bierhaus A,Fasching P,et al.Endothel in 1 transcription is controlled by rluclear factor-kappa B in AGE-stimulated cultured endothelial cells[J].Diabetes,2000.49:1561-1570.
[46]李俊.2型糖尿病心血管并发症发病机制的研究进展[J].现代诊断与治疗,2005,16(5):295-297.
[47]林少达,林楚佳.5-羟色胺与糖尿病心血管并发症的关系[J].中国糖尿病杂志,2006,14(2):152-152,151.
[48]赵海燕,张晓青.脂联素研究进展[J].国外医学:内分泌学分册,2003,23(B04):59-62.
[49]刘红,洪兵,夏宁,等.血清脂联素水平与2型糖尿病心血管病变的相关性[J].中国临床康复,2004,8(36):8214-8216.
[50]张文强,林哲章.CD40-CD40L与糖尿病心血管并发症相关性研究[J].实用糖尿病杂志,2006,2(3):51-52.
[51]胡绍文,郭瑞林,童光焕,等.实用糖尿病学(第2版)[M].北京:人民军医出版社.2003,309.
[52]张韶英.2型糖尿病合并冠心病患者24h动态心电图临床分析[J].现代中西医结合杂志,2005,14(9):1145-1146.
[53]耿黎明.心电图及冠脉造影诊断冠心病的对比分析[J].实用心电学杂志,2008,17(4):270-271.
[54]焦方惠.糖尿病性冠心病心肌缺血的动态心电图分析[J].社区医学杂志,2006,4(8):39-40.
[55]段军,汪小萍,邹凤军.糖尿病及糖耐量减低合并冠心病患者的超声心动图特点 [J].临床荟萃,2004,19(19):1084-1086.
[56]刘雪玲.超声心动图对糖尿病性心脏病的诊断价值[J].临床超声医学杂志,2002,4(2):106-107.
[57]耿黎明.心电图及冠脉造影诊断冠心病的对比分析[J].实用心电学杂志,2008,17(4):270-271.
[58]刘新民,张锦.实用内分泌疾病诊疗手册[M].北京:人民军医出版社.2008,575-578.
[59]郭颖,丁鹤林,傅祖植.糖尿病心血管并发症的药物防治[J].中国处方药,2005(6):54-57.
[60]Salpeter S,张益民(摘),李幼姬(校).2型糖尿病患者服用二甲双胍发生乳酸酸中毒的危险[J].中国中西医结合肾病杂志,2006,7(9):552-552.
[61]无.二甲双胍能有效干预心血管危险因素[J].糖尿病之友,2008(6):90-90.
[62]李宏亮,杨文英.噻唑烷二酮类药物对心血管疾病发生风险的影响-来自第43届EASD年会的报道[J].药品评价,2008,5(1):23-24,28.
[63]杨宝峰.药理学[M].北京:人民卫生出版社,2006:273-276.
[64]金凤表,侯瑞田,郭丹杰.糖尿病合并冠心病的治疗进展[J].临床荟萃,2005,20(13):773-775.
[65]史清海,路西春.胱抑素C的生物学特性及其测定的临床应用[J].西北国防医学杂志,2005,26(6):445-447.
[66]苏彩芳,高岩.血清胱抑素C测定临床意义探讨[J].中国病案,2006,7(6):47-48.
[67]黄君富.血清胱抑素C测定的临床意义及方法学进展[J].国外医学:临床生物化学与检验学分册,1999,20(1):8-10.
[68]徐志强(综述),王骏,王鸣和(审校).胱抑素C与冠心病相关性的研究进展[J].心血管病学进展,2008,29(1):64-67.
[69]侯振江(综述),魏明竞(审校).胱抑素C及其检测方法研究进展[J].国际检验医学杂志,2007,28(11):1013-1015.
[70]史清海,路西春.胱抑素C的生物学特性及其测定的临床应用[J].西北国防医学杂志,2005,26(6):445-447.
[71]侯振江(综述),魏明竞(审校).胱抑素C及其检测方法研究进展[J].国际检验医学杂志,2007,28(11):1013-1015.
[72]陈治奎,葛长江,胡申江.胱抑素C与心血管疾病的关系[J].生理科学进展,2003,34(3):269-271.
[73]Luc G,Bard JM,Lesueur C,et al.Plasma cystatin-C and development of coronary heart disease:The PRIME Study[J].Atherosclerosis,2006, 185(2):375-380.
[74]Koenig W,Twardella D,BrennerH,et al.Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events:more than simply a marker of glomerular filtration rate[J].Clin Chem,2005,51(2):321-327.
[75]Jernberg T,Lindahl B,James S,et al.Cystatin C:a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome[J].Circulation,2004,110(16):2342-2348.
[76]Shlipak MG,Sarnak MJ,Katz R,et al.Cystatin C and the risk of death and cardiovascular events among elderly persons[J].N Engl J Med,2005,352(20):2049-2060.
[77]杨继红,王雪东,吴华.Cystatin C的临床应用[J].中国中西医结合肾病杂志,2006,7(8):430-432.
[78]郑淑蓓,季亢挺,周野,等.冠心病患者检测血清半胱氨酸蛋白酶抑制剂C的意义[J].浙江实用医学,2007,12(4):236-237.
[79]李凯,刘伯学,蔡天志,等.半胱氨酸蛋白酶抑制剂C与左室射血分数关系的临床研究[J].实用心脑肺血管病杂志,2007,15(12):912-913.
[80]马静,解汝娟.慢性肾脏病非透析患者血清半胱氨酸蛋白酶抑制剂C与心脏功能和生化指标的关系[J].中国血液净化,2008,7(4):183-187.
[81]陈治奎,葛长江,胡申江.胱抑素C与心血管疾病的关系[J].生理科学进展,2003,34(3):269-271.
[82]任豫申,许迅辉.血清胱抑素C:在肌酐盲范围检测GFR的标志物[J].国外医学:泌尿系统分册,2002,22(5):318-320.
[83]杨晓晖,钟柳娜,吕仁和.糖尿病心脏病中医药临床研究述评[J].中国医药学报.2003;18(7):430.
[84]徐梓辉.糖尿病并发冠心病中医药治疗进展及评述[J].中国中医药信息杂志,2001;8(12):18.
[85]章小平.益气养阴活血法治疗糖尿病合并冠心病研究进展[J].安徽中医学院学报,2001,20(1):60-62.
[86]牛国栋,牛廷银.糖尿病性心脏病的辨证论治[J].中国自然医学杂志,2001,3(4):207.
[87]冯建华.活血法在糖尿病并发症中的应用[J].山东中医学院学报,1993,17(6):23-26.
[88]胡继玲.止消通脉清热饮治疗糖尿病合并冠心病的临床观察[J].中国医药学报, 1996,11(3):57-58.
[89]屠伯言.糖尿病兼有冠心病的辨证分型与治疗[J].山东中医杂志,1983;(2):11.
[90]胡东鹏,倪青.巧定病性明标本 中西合参论治疗--辨治糖尿病心脏病的经验[J].辽宁中医杂志,2000,27(7):289-291.
[91]丁邦晗,张敏州,张崟,等.胸痹心痛并发高血压、糖尿病的临床证型特点分析[J].中西医结合心脑血管病杂志,2004,2(3):125-127.
[92]李赛美,熊曼琪.不同治法对糖尿病大鼠心脏病变影响的实验研究[J].新中医,1999,31(10):39-41.
[93]安荣,丁延平,王凤,等.糖心乐对实验性糖尿病性心肌病大鼠心肌超微结构的影响[J].陕西中医学院学报.2007;30(5):68-70.
[94]徐梓辉,周世文,陈大舜,等.降糖舒心颗粒对糖尿病合并动脉粥样硬化大鼠主动脉LOX-1 mRNA表达的影响[J].中国中医急症.2004;13(12):831-832.
[95]胡成俊,张友云.大鼠Ⅱ型糖尿病心肌细胞凋亡及其调控基因表达的变化[J].解剖学杂志,2002,25(6):532-536.
[96]栗明,栗德林,孟庆刚,等.芪玄益心胶囊对糖尿病大鼠急性缺血心肌NF-κ Bp50、IκBα、IL-1β及其mRNA的影响[J].北京中医药大学学报,2007,30(1):40-44.
[97]梁隽婷,胡淑宏,邢国利,等.益气养阴活血法治疗糖尿病性心脏病疗效观察[J].中医药信息.2003,20(3):39.
[98]苏诚炼,肖月星.中医辨证论治“糖心病”[J].糖尿病之友,2006.9:48-49.
[99]林兰.中西医结合糖尿病研究进展[J].北京:海洋出版社,2000;358-361.
[100]郭维琴.糖尿病合并冠心病中药使用分七型[J].糖尿病之友,2008(3):52-53.
[101]杨兵,梁翠微.老年糖尿病合并冠心病中医辨治探讨[J].光明中医,2005,20(4):30-31.
[102]付亚龙.糖尿病合并冠心病的中医诊治[J].糖尿病之友,2002,1(3):42-43.
[103]刘三运,宋培瑚,张庆年.心舒丸治疗2型糖尿病合并冠心病130例临床观察[J].新中医,2008(1):40-42.
[104]陈大舜,徐梓辉,周世文.降糖舒心颗粒治疗2型糖尿病并发冠心病的临床观察[J].湖南中医学院学报,2003,23(3):30-33.
[105]薛军,陈镜合.开心胶囊对糖尿病性心脏病患者心肌缺血和血液流变学的影响[J].江苏中医药.2006,27(2):24-26.
[106]魏玲玲.益心舒胶囊治疗糖尿病性冠心病的临床观察[J].中国中西医结合杂志,2008,28(4):374-375.
[107]张军,刘玉洁.补益心气法治疗糖尿病合并冠心病心绞痛60例疗效观察[J].新 中医,2005,37(9):40-42.
[108]吴夏棉,刘礼乐.中西医结合治疗糖尿病合并冠心病:附30例分析[J].实用医学杂志,1995,11(10):695-696.
[109]栗德林,闰秀峰.糖冠康治疗Ⅱ型糖尿病合并冠心病的临床与机理研究[J].中医药学报,2003,31(1):11-12.
[110]范世平,饶振芳,马晓霖,等.糖心宁胶囊治疗糖尿病性冠心病的临床研究[J].新中医,2001,33(1):34-36.
[111]韩文宝.益气通络胶囊治疗糖尿病合并冠心病心绞痛60例临床观察[J].中国现代医药杂志,2007,9(8):78-79.
[112]杜廷海,吕小红,吕靖中.消渴安胶囊治疗糖尿病性冠心病150例临床观察[J].中国中医药科技,2001,8(2):117-118.
[113]陈艳.糖尿病性心脏病--单味中药的选用[J].糖尿病新世界.2006;3:51.
[114]Connell FA louden JM.Diabetes mortality in peraona under 4s years of age[J].Am j Public Health,1983,73:1174.
[115]中华人民共和国卫生部制定发布.中药新药临床研究指导原则·第一辑[M].1993:41-45,215-218.
[116][金]李东垣撰.文魁,丁国华整理.兰室秘藏[M].北京:人民卫生出版社.2005,第1版,30.
[117][清]叶天士撰.苏礼等整理.临证指南医案[M].北京:人民卫生出版社.2006,272.
[118][清]张隐庵 集注.孙国中,方向红 点校.黄帝内经素问集注[M].北京:学苑出版社.2002,345.
[119]任应秋.任应秋论医集[M].北京:人民卫生出版社.1984,507-508.
[120]林兰.糖尿病的中西医结合论治[M].北京:北京科学技术出版社.1992,255-256.
[121][明]张介宾 著.李继明,王大淳,王小平,等整理.景岳全书[M].北京:人民卫生出版社.2007,第1版:424.
[122]刘孝培,邱宗志,周志枢,等.景岳全书·杂证谟[M].重庆:重庆大学出版社.1988,第1版:57-58.
[123][清]冯兆张 纂辑.田思胜,高萍,戴敬敏,等校注.冯氏锦囊秘录[M].北京:中国中医药出版社.1996,第1版:66.
[124]李鼎.经络学[M].上海:上海科学技术出版社.1995,第1版:49-51,67-70.
[125][明]龚廷贤 撰.鲁兆麟 主校,彭建中,程昭 点校.寿世保元[M].北京:人民卫生出版社.1993,第1版:139.
[126]杜军强.糖尿病中医药防治指南[M].北京:中国中医药出版社.2003,12.
[127]林兰.糖尿病的中西医结合论治[M].北京:北京科学技术出版社.1992,8.
[128]任继学.刚柔相济 勿忘温阳活血 通补并行 当求血肉有情[J].中国乡村医生,1998,14(7):36-37.
[129]韩天雄,孔令越,施红.颜德馨教授运用温阳法治疗心血管病经验[J].中国中医急症,2008,17(4):488-489.
[130]姚沛雨.活血化瘀法在糖尿病中的应用[J].河南中医,2007,27(7):75-75.
[131]马宗超,唐智宏,张海.谈附子的药理及临床应用[J].时珍国医国药,2004,15(11):790.
[132]马宗超,唐智宏,张海.谈附子的药理及临床应用[J].时珍国医国药,2004,15(11):790.
[133]阎爱荣,张宏.附子的药理研究[J].中国药物与临床,2008,8(9):745-747.
[134]刘秀梅.桂枝在治疗冠心病临床中作用的体会[J].新医学导刊,2008,7(2):126-126.
[135]冯大千.桂枝治疗心绞痛[J].陕西中医,2003,24(8):754-755.
[136]高学敏.中药学[M].北京:人民卫生出版社,2000:192.
[137]吕超.桂枝温经能脉作用的实验观察[J].上海中医药杂志,1993;(12):34-36.
[138]侯家玉.中药药理学[M].北京:中国中医药出版社,2002:30-31,217-219.
[139]于辉,李春香,宫凌涛,等.甘草的药理作用概述[J].现代生物医学进展,2006,6(4):77-79.
[140]王秋,王占石.桂枝甘草汤温经通脉的药效学研究[J].中医药研究,2002,18(5):41-42.
[141]宋立人,洪恂,丁绪亮,等.现代中药学大辞典[M].北京:人民卫生出版社,2001,第1版:1655.
[142]张弢,沈文芳,朱俊.瓜蒌对心血管系统的药理作用及临床应用[J].中国乡村医药,2007,14(11):52-52.
[143]张卿,高尔.薤白的研究进展[J].中国中药杂志,2003,28(2):105-107.
[144]宋立人,洪恂,丁绪亮,等.现代中药学大辞典[M].北京:人民卫生出版社,2001,第1版:2409-2411.
[145]涂莉.半夏的药理学实验研究进展[J].临床和实验医学杂志,2006,5(11):1846.
[146]李丽,王慧娟,盖成万.半夏的药理和临床研究进展[J].中医药信息,2006,23(5):38-40.
[147]焦红军.党参的药理作用及其临床应用[J].临床医学,2005,25(4):92-92,89.
[148]朱焰,魏均娴.党参药用植物研究状况[J].天然产物研究与开发,1994,6(1):70-75.
[149]陈华萍,吴万征.白术的研究进展[J].广东药学,2002,12(5):19-21.
[150]蒲含林,王正濂,黄巧娟,等.双白术内酯对豚鼠离体心房肌的作用[J].中国药理学通报,2000,16(1):60-62.
[151]叶水泉.上品仙药--茯苓[J].现代养生,2004,(5):37.
[152]李玉平,李林.茯苓的临床新用途[J].职业与健康,2000,16(8):122-123.
[153]贡云华,蒋家雄.三七皂甙C1对四氧嘧啶糖尿病小鼠的降血糖作用[J].药学学报,1991,26(2):81-85.
[154]甘雨,徐惠波,孙晓波.三七总皂苷的药理作用研究进展[J].时珍国医国药,2007,18(5):1251-1252.
[155]占宏静.中药丹参药理作用新发展[J].健康大视野:医学分册,2006,14(8):77.
[156]雷载权.中药学[M].上海:上海科学技术出版社.1995:205.
[157]南京中医药大学编著.中药大辞典[M].上海:上海科学技术出版社.2006.
[158]胡烈.玉米须临床新用[J].中国临床医生,2000,28(8):40-41.
[159]郭颖,丁鹤林,傅祖植,等.糖尿病心血管并发症的药物防治[J].中国处方药,2005(6):54-57.
[160]金文胜.控制糖尿病心血管危险因素研究进展[J].继续医学教育,2005,19(1):14-17.
[161]王建华.控制血糖波动减少糖尿病慢性并发症[J].临床药物治疗杂志,2007,5(4):38-39,4.
[162]耿黎明.2型糖尿病合并冠心病患者心电图及冠脉造影结果的分析[J].临床心电学杂志,2008,17(6):429-431.
[163]陈灏珠.实用内科学·第12版[M].北京:人民卫生出版社.2006,1469.
[164]张春芳,周亚滨,陈会君,等.益气温阳、活血化瘀方对兔血管成形术后再狭窄PDGF-B mRNA表达的影响[J].中国介入影像与治疗学,2006,3(2):145-148.
[165]欧阳真理.益气温阳宣痹通络法治疗冠心病心绞痛60例[J].深圳中西医结合杂志,2006,16(1):49-49.
[166]王昃睿,王晓伟.益气温阳活血通络方治疗冠心病心绞痛101例[J].中国民间疗法,2007,15(4):19-20.
[167]周兆华,顾庆华,蒋烈,等.2型糖尿病合并冠心病患者的血脂异常分析[J].井冈山学院学报:综合版,2006;27(12):107-109.
[168]崔国敏,李振娥.糖尿病合并冠心病危险因素分析[J].济宁医学院学报,2000, 23(1):66-67.
[169]周勇,孙虹云.2型糖尿病合并冠心病的危险因素分析[J].蚌埠医学院学报,2003,28(1):31-32.
[170]郭颖,丁鹤林,傅祖植,等.糖尿病心血管并发症的药物防治[J].中国处方药,2005(6):54-57.
[171]刘国良.糖尿病诊断治疗的最新进展[J].中国实用内科杂志,2000,20(1):29-32.
[172]司徒玉,黄萍萍.肾功能不同损害期患者血清胱抑素C与血肌酐、肌酐清除率的相关性研究[J].广东医学院学报,2004,22(2):137-138.
[173]张微,张波,吕田,等.半胱氨酸蛋白酶抑制物C在心力衰竭的临床意义[J].岭南心血管病杂志,2008,14(5):338-340.
[174]马静,解汝娟.慢性肾脏病非透析患者血清半胱氨酸蛋白酶抑制剂C与心脏功能和生化指标的关系[J].中国血液净化,2008,7(4):183-187.
[175]李凯,刘伯学,蔡天志,等.半胱氨酸蛋白酶抑制剂C与左室射血分数关系的临床研究[J].实用心脑肺血管病杂志,2007,15(12):912-913.
[2]胡绍文,郭瑞林,童光焕,等.实用糖尿病学(第2版)[M].北京:人民军医出版社.2003,304.
[3]何宇梅,郭庆畲,苏苹.2型糖尿病与心血管病危险的关系[J].医学综述,2001,7(6):354-355.
[4]徐成斌.糖尿病与心血管并发症[J].当代医学,2001,7(2):45-48.
[5]刘新民,张锦.实用内分泌疾病诊疗手册[M].北京:人民军医出版社.2008,575.
[6]钱薇薇,董砚虎.糖尿病并心血管病变的诊治进展[J].山东医药,2000,40(5):38-38.
[7]肖新华.糖尿病与心血管病[J].中国中西医结合杂志,2007,27(8):678-679.
[8]陈灏珠.实用内科学·第12版[M].北京:人民卫生出版社.2006,1028.
[9]单文华.糖尿病冠心病的临床特征[J].家庭医学,2006,(1):42-43.
[10]李勇,赖晓阳.2型糖尿病合并冠心病冠脉造影特点和支架植入治疗进展[J].实用临床医学(江西),2008,9(3):136-138.
[11]陶凯忠.高血糖与糖尿病血管病变及机制[J].中国糖尿病杂志,2001,9(5):306-308.
[12]曹国良,乔永芳.2型糖尿病餐后高血糖与心血管危险[J].医学与哲学,2004,25(11):43-44,57.
[13]傅一明.胰岛素抵抗的研究新进展[J].新医学,1999,30(12):733-734.
[14]祝之明.洞察胰岛素抵抗与糖尿病相关心血管危险因素[J].中华医学信息导报,2006,21(7):21.
[15]沈利亚.胰岛素抵抗与心血管疾病[J].江汉大学学报:自然科学版,2003,31(3):70-73.
[16]无.消除胰岛素抵抗--降低糖尿病心血管病变的关键[J].糖尿病之友,2003,
2(4):71-71.
[17]陈莉明.糖尿病心血管病变的研究现状[J].国外医学:内分泌学分册,2003,23(1):59-61.
[18]侯迎会,马立侠.他汀类药对糖尿病合并冠状动脉粥样硬化性心脏病的作用[J].中国热带医学,2005,5(2):310-311.
[19]何文姬,卜建宏,高书荣,等.2型糖尿病并发冠心病危险因素分析[J].医学综述,2007,13(7):536-537.
[20]胡量子,杨波,宋艳红.2型糖尿病伴冠心病患者超敏C反应蛋白的观察[J].临床心血管病杂志,2007,23(10):795-796.
[21]郭丽君.2型糖尿病伴冠心病C反应蛋白和尿酸变化的临床观察[J].实用医技杂志,2008,15(24):3262-3263.
[22]陈莉明.糖尿病心血管病变的研究现状[J].国外医学:内分泌学分册,2003,23(1):59-61.
[23]周英,李方雄.糖尿病合并冠心病患者血浆hs-CRP和尿酸水平的变化及临床意义[J].疑难病杂志,2008,7(1):8-10.
[24]徐懿,李月华.糖尿病合并冠状动脉粥样硬化性心脏病的发病及其相关特征[J].中国临床康复,2006,10(20):130-132.
[25]张晓梅,王正梅.尿微量白蛋白检测对Ⅱ型糖尿病合并冠心病患者的临床意义[J].中国医药指南,2006,11:56-57.
[26]陈伯良.尿微量白蛋白测定在糖尿病肾病及冠心病诊断中的应用[J].中国热带医学,2006,6(5):803.
[27]陈新华,高向玲.75例糖尿病合并冠心病患者尿微量白蛋白检测分析[J].山东医药,2006,46(17):56-57.
[28]田晓艳,秦艳华.2型糖尿病患者微量白蛋白尿与糖尿病性心脏病临床分析[J].中国当代医学,2007,6(12):32-33.
[29]刘芳,张新书,王佑民,等.QTVI对2型糖尿病患者微量白蛋白尿与左心收缩功能的相关性研究[J].安徽医科大学学报,2007,42(1):73-75.
[30]张晓野,郭战利,左岩霞,等.尿微量白蛋白水平与糖尿病合并冠心病患者心功能的相关性分析[J].山东医药,2008,48(2):51-52.
[31]陈立东,杨文东.糖尿病患者尿微量白蛋白与冠心病的关系[J].山西医科大学学报,2006,37(6):625-627.
[32]郑法雷,章友康.肾脏病临床与进展[M].北京:人民军医出版社,2005,11.
[33]韦秀英.2型糖尿病病人微量白蛋白尿的危险因素分析[J].右江民族医学院学报,2004,3:333-335.
[34]郭凡.2型糖尿病患者微量白蛋白尿与缺血性心脏病的相关分析[J].辽宁医学杂志,2006,20(2):81-82.
[35]宁静(综述),陈军(审校).同型半胱氨酸--心血管疾病新的重要检测指标[J].国际检验医学杂志,2007,28(4):369-369,372.
[36]周灵丽,卢纹凯.2型糖尿病患者血浆总同型半胱氨酸水平与大血管病变的关系[J].中国糖尿病杂志,2003,11(4):265-267.
[37]吴乃君,陈冬,金秀平,等.2型糖尿病患者血清同型半胱氨酸检测的临床意义 [J].山东医药,2006,46(34):51-52.
[38]李刚,周兴文.新的冠心病危险因素[J].心血管病学进展,2005,26(3):266-271.
[39]陈军政.2型糖尿病肾病患者血清胱抑素C的检测及意义[J].微循环学杂志,2007,17(3):58-59.
[40]苏彩芳,高岩.血清胱抑素C测定临床意义探讨[J].中国病案,2006,7(6):47-48.
[41]黄君富.血清胱抑素C测定的临床意义及方法学进展[J].国外医学:临床生物化学与检验学分册,1999,20(1):8-10.
[42]徐志强(综述),王骏,王鸣和(审校).胱抑素C与冠心病相关性的研究进展[J].心血管病学进展,2008,29(1):64-67.
[43]陈治奎,葛长江,胡申江.胱抑素C与心血管疾病的关系[J].生理科学进展,2003,34(3):269-271.
[44]任爱英,王凡.血清胱抑素C的临床应用及研究[J].检验医学与临床,2008,(1):32-34.
[45]Quehenberger P,Bierhaus A,Fasching P,et al.Endothel in 1 transcription is controlled by rluclear factor-kappa B in AGE-stimulated cultured endothelial cells[J].Diabetes,2000.49:1561-1570.
[46]李俊.2型糖尿病心血管并发症发病机制的研究进展[J].现代诊断与治疗,2005,16(5):295-297.
[47]林少达,林楚佳.5-羟色胺与糖尿病心血管并发症的关系[J].中国糖尿病杂志,2006,14(2):152-152,151.
[48]赵海燕,张晓青.脂联素研究进展[J].国外医学:内分泌学分册,2003,23(B04):59-62.
[49]刘红,洪兵,夏宁,等.血清脂联素水平与2型糖尿病心血管病变的相关性[J].中国临床康复,2004,8(36):8214-8216.
[50]张文强,林哲章.CD40-CD40L与糖尿病心血管并发症相关性研究[J].实用糖尿病杂志,2006,2(3):51-52.
[51]胡绍文,郭瑞林,童光焕,等.实用糖尿病学(第2版)[M].北京:人民军医出版社.2003,309.
[52]张韶英.2型糖尿病合并冠心病患者24h动态心电图临床分析[J].现代中西医结合杂志,2005,14(9):1145-1146.
[53]耿黎明.心电图及冠脉造影诊断冠心病的对比分析[J].实用心电学杂志,2008,17(4):270-271.
[54]焦方惠.糖尿病性冠心病心肌缺血的动态心电图分析[J].社区医学杂志,2006,4(8):39-40.
[55]段军,汪小萍,邹凤军.糖尿病及糖耐量减低合并冠心病患者的超声心动图特点 [J].临床荟萃,2004,19(19):1084-1086.
[56]刘雪玲.超声心动图对糖尿病性心脏病的诊断价值[J].临床超声医学杂志,2002,4(2):106-107.
[57]耿黎明.心电图及冠脉造影诊断冠心病的对比分析[J].实用心电学杂志,2008,17(4):270-271.
[58]刘新民,张锦.实用内分泌疾病诊疗手册[M].北京:人民军医出版社.2008,575-578.
[59]郭颖,丁鹤林,傅祖植.糖尿病心血管并发症的药物防治[J].中国处方药,2005(6):54-57.
[60]Salpeter S,张益民(摘),李幼姬(校).2型糖尿病患者服用二甲双胍发生乳酸酸中毒的危险[J].中国中西医结合肾病杂志,2006,7(9):552-552.
[61]无.二甲双胍能有效干预心血管危险因素[J].糖尿病之友,2008(6):90-90.
[62]李宏亮,杨文英.噻唑烷二酮类药物对心血管疾病发生风险的影响-来自第43届EASD年会的报道[J].药品评价,2008,5(1):23-24,28.
[63]杨宝峰.药理学[M].北京:人民卫生出版社,2006:273-276.
[64]金凤表,侯瑞田,郭丹杰.糖尿病合并冠心病的治疗进展[J].临床荟萃,2005,20(13):773-775.
[65]史清海,路西春.胱抑素C的生物学特性及其测定的临床应用[J].西北国防医学杂志,2005,26(6):445-447.
[66]苏彩芳,高岩.血清胱抑素C测定临床意义探讨[J].中国病案,2006,7(6):47-48.
[67]黄君富.血清胱抑素C测定的临床意义及方法学进展[J].国外医学:临床生物化学与检验学分册,1999,20(1):8-10.
[68]徐志强(综述),王骏,王鸣和(审校).胱抑素C与冠心病相关性的研究进展[J].心血管病学进展,2008,29(1):64-67.
[69]侯振江(综述),魏明竞(审校).胱抑素C及其检测方法研究进展[J].国际检验医学杂志,2007,28(11):1013-1015.
[70]史清海,路西春.胱抑素C的生物学特性及其测定的临床应用[J].西北国防医学杂志,2005,26(6):445-447.
[71]侯振江(综述),魏明竞(审校).胱抑素C及其检测方法研究进展[J].国际检验医学杂志,2007,28(11):1013-1015.
[72]陈治奎,葛长江,胡申江.胱抑素C与心血管疾病的关系[J].生理科学进展,2003,34(3):269-271.
[73]Luc G,Bard JM,Lesueur C,et al.Plasma cystatin-C and development of coronary heart disease:The PRIME Study[J].Atherosclerosis,2006, 185(2):375-380.
[74]Koenig W,Twardella D,BrennerH,et al.Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events:more than simply a marker of glomerular filtration rate[J].Clin Chem,2005,51(2):321-327.
[75]Jernberg T,Lindahl B,James S,et al.Cystatin C:a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome[J].Circulation,2004,110(16):2342-2348.
[76]Shlipak MG,Sarnak MJ,Katz R,et al.Cystatin C and the risk of death and cardiovascular events among elderly persons[J].N Engl J Med,2005,352(20):2049-2060.
[77]杨继红,王雪东,吴华.Cystatin C的临床应用[J].中国中西医结合肾病杂志,2006,7(8):430-432.
[78]郑淑蓓,季亢挺,周野,等.冠心病患者检测血清半胱氨酸蛋白酶抑制剂C的意义[J].浙江实用医学,2007,12(4):236-237.
[79]李凯,刘伯学,蔡天志,等.半胱氨酸蛋白酶抑制剂C与左室射血分数关系的临床研究[J].实用心脑肺血管病杂志,2007,15(12):912-913.
[80]马静,解汝娟.慢性肾脏病非透析患者血清半胱氨酸蛋白酶抑制剂C与心脏功能和生化指标的关系[J].中国血液净化,2008,7(4):183-187.
[81]陈治奎,葛长江,胡申江.胱抑素C与心血管疾病的关系[J].生理科学进展,2003,34(3):269-271.
[82]任豫申,许迅辉.血清胱抑素C:在肌酐盲范围检测GFR的标志物[J].国外医学:泌尿系统分册,2002,22(5):318-320.
[83]杨晓晖,钟柳娜,吕仁和.糖尿病心脏病中医药临床研究述评[J].中国医药学报.2003;18(7):430.
[84]徐梓辉.糖尿病并发冠心病中医药治疗进展及评述[J].中国中医药信息杂志,2001;8(12):18.
[85]章小平.益气养阴活血法治疗糖尿病合并冠心病研究进展[J].安徽中医学院学报,2001,20(1):60-62.
[86]牛国栋,牛廷银.糖尿病性心脏病的辨证论治[J].中国自然医学杂志,2001,3(4):207.
[87]冯建华.活血法在糖尿病并发症中的应用[J].山东中医学院学报,1993,17(6):23-26.
[88]胡继玲.止消通脉清热饮治疗糖尿病合并冠心病的临床观察[J].中国医药学报, 1996,11(3):57-58.
[89]屠伯言.糖尿病兼有冠心病的辨证分型与治疗[J].山东中医杂志,1983;(2):11.
[90]胡东鹏,倪青.巧定病性明标本 中西合参论治疗--辨治糖尿病心脏病的经验[J].辽宁中医杂志,2000,27(7):289-291.
[91]丁邦晗,张敏州,张崟,等.胸痹心痛并发高血压、糖尿病的临床证型特点分析[J].中西医结合心脑血管病杂志,2004,2(3):125-127.
[92]李赛美,熊曼琪.不同治法对糖尿病大鼠心脏病变影响的实验研究[J].新中医,1999,31(10):39-41.
[93]安荣,丁延平,王凤,等.糖心乐对实验性糖尿病性心肌病大鼠心肌超微结构的影响[J].陕西中医学院学报.2007;30(5):68-70.
[94]徐梓辉,周世文,陈大舜,等.降糖舒心颗粒对糖尿病合并动脉粥样硬化大鼠主动脉LOX-1 mRNA表达的影响[J].中国中医急症.2004;13(12):831-832.
[95]胡成俊,张友云.大鼠Ⅱ型糖尿病心肌细胞凋亡及其调控基因表达的变化[J].解剖学杂志,2002,25(6):532-536.
[96]栗明,栗德林,孟庆刚,等.芪玄益心胶囊对糖尿病大鼠急性缺血心肌NF-κ Bp50、IκBα、IL-1β及其mRNA的影响[J].北京中医药大学学报,2007,30(1):40-44.
[97]梁隽婷,胡淑宏,邢国利,等.益气养阴活血法治疗糖尿病性心脏病疗效观察[J].中医药信息.2003,20(3):39.
[98]苏诚炼,肖月星.中医辨证论治“糖心病”[J].糖尿病之友,2006.9:48-49.
[99]林兰.中西医结合糖尿病研究进展[J].北京:海洋出版社,2000;358-361.
[100]郭维琴.糖尿病合并冠心病中药使用分七型[J].糖尿病之友,2008(3):52-53.
[101]杨兵,梁翠微.老年糖尿病合并冠心病中医辨治探讨[J].光明中医,2005,20(4):30-31.
[102]付亚龙.糖尿病合并冠心病的中医诊治[J].糖尿病之友,2002,1(3):42-43.
[103]刘三运,宋培瑚,张庆年.心舒丸治疗2型糖尿病合并冠心病130例临床观察[J].新中医,2008(1):40-42.
[104]陈大舜,徐梓辉,周世文.降糖舒心颗粒治疗2型糖尿病并发冠心病的临床观察[J].湖南中医学院学报,2003,23(3):30-33.
[105]薛军,陈镜合.开心胶囊对糖尿病性心脏病患者心肌缺血和血液流变学的影响[J].江苏中医药.2006,27(2):24-26.
[106]魏玲玲.益心舒胶囊治疗糖尿病性冠心病的临床观察[J].中国中西医结合杂志,2008,28(4):374-375.
[107]张军,刘玉洁.补益心气法治疗糖尿病合并冠心病心绞痛60例疗效观察[J].新 中医,2005,37(9):40-42.
[108]吴夏棉,刘礼乐.中西医结合治疗糖尿病合并冠心病:附30例分析[J].实用医学杂志,1995,11(10):695-696.
[109]栗德林,闰秀峰.糖冠康治疗Ⅱ型糖尿病合并冠心病的临床与机理研究[J].中医药学报,2003,31(1):11-12.
[110]范世平,饶振芳,马晓霖,等.糖心宁胶囊治疗糖尿病性冠心病的临床研究[J].新中医,2001,33(1):34-36.
[111]韩文宝.益气通络胶囊治疗糖尿病合并冠心病心绞痛60例临床观察[J].中国现代医药杂志,2007,9(8):78-79.
[112]杜廷海,吕小红,吕靖中.消渴安胶囊治疗糖尿病性冠心病150例临床观察[J].中国中医药科技,2001,8(2):117-118.
[113]陈艳.糖尿病性心脏病--单味中药的选用[J].糖尿病新世界.2006;3:51.
[114]Connell FA louden JM.Diabetes mortality in peraona under 4s years of age[J].Am j Public Health,1983,73:1174.
[115]中华人民共和国卫生部制定发布.中药新药临床研究指导原则·第一辑[M].1993:41-45,215-218.
[116][金]李东垣撰.文魁,丁国华整理.兰室秘藏[M].北京:人民卫生出版社.2005,第1版,30.
[117][清]叶天士撰.苏礼等整理.临证指南医案[M].北京:人民卫生出版社.2006,272.
[118][清]张隐庵 集注.孙国中,方向红 点校.黄帝内经素问集注[M].北京:学苑出版社.2002,345.
[119]任应秋.任应秋论医集[M].北京:人民卫生出版社.1984,507-508.
[120]林兰.糖尿病的中西医结合论治[M].北京:北京科学技术出版社.1992,255-256.
[121][明]张介宾 著.李继明,王大淳,王小平,等整理.景岳全书[M].北京:人民卫生出版社.2007,第1版:424.
[122]刘孝培,邱宗志,周志枢,等.景岳全书·杂证谟[M].重庆:重庆大学出版社.1988,第1版:57-58.
[123][清]冯兆张 纂辑.田思胜,高萍,戴敬敏,等校注.冯氏锦囊秘录[M].北京:中国中医药出版社.1996,第1版:66.
[124]李鼎.经络学[M].上海:上海科学技术出版社.1995,第1版:49-51,67-70.
[125][明]龚廷贤 撰.鲁兆麟 主校,彭建中,程昭 点校.寿世保元[M].北京:人民卫生出版社.1993,第1版:139.
[126]杜军强.糖尿病中医药防治指南[M].北京:中国中医药出版社.2003,12.
[127]林兰.糖尿病的中西医结合论治[M].北京:北京科学技术出版社.1992,8.
[128]任继学.刚柔相济 勿忘温阳活血 通补并行 当求血肉有情[J].中国乡村医生,1998,14(7):36-37.
[129]韩天雄,孔令越,施红.颜德馨教授运用温阳法治疗心血管病经验[J].中国中医急症,2008,17(4):488-489.
[130]姚沛雨.活血化瘀法在糖尿病中的应用[J].河南中医,2007,27(7):75-75.
[131]马宗超,唐智宏,张海.谈附子的药理及临床应用[J].时珍国医国药,2004,15(11):790.
[132]马宗超,唐智宏,张海.谈附子的药理及临床应用[J].时珍国医国药,2004,15(11):790.
[133]阎爱荣,张宏.附子的药理研究[J].中国药物与临床,2008,8(9):745-747.
[134]刘秀梅.桂枝在治疗冠心病临床中作用的体会[J].新医学导刊,2008,7(2):126-126.
[135]冯大千.桂枝治疗心绞痛[J].陕西中医,2003,24(8):754-755.
[136]高学敏.中药学[M].北京:人民卫生出版社,2000:192.
[137]吕超.桂枝温经能脉作用的实验观察[J].上海中医药杂志,1993;(12):34-36.
[138]侯家玉.中药药理学[M].北京:中国中医药出版社,2002:30-31,217-219.
[139]于辉,李春香,宫凌涛,等.甘草的药理作用概述[J].现代生物医学进展,2006,6(4):77-79.
[140]王秋,王占石.桂枝甘草汤温经通脉的药效学研究[J].中医药研究,2002,18(5):41-42.
[141]宋立人,洪恂,丁绪亮,等.现代中药学大辞典[M].北京:人民卫生出版社,2001,第1版:1655.
[142]张弢,沈文芳,朱俊.瓜蒌对心血管系统的药理作用及临床应用[J].中国乡村医药,2007,14(11):52-52.
[143]张卿,高尔.薤白的研究进展[J].中国中药杂志,2003,28(2):105-107.
[144]宋立人,洪恂,丁绪亮,等.现代中药学大辞典[M].北京:人民卫生出版社,2001,第1版:2409-2411.
[145]涂莉.半夏的药理学实验研究进展[J].临床和实验医学杂志,2006,5(11):1846.
[146]李丽,王慧娟,盖成万.半夏的药理和临床研究进展[J].中医药信息,2006,23(5):38-40.
[147]焦红军.党参的药理作用及其临床应用[J].临床医学,2005,25(4):92-92,89.
[148]朱焰,魏均娴.党参药用植物研究状况[J].天然产物研究与开发,1994,6(1):70-75.
[149]陈华萍,吴万征.白术的研究进展[J].广东药学,2002,12(5):19-21.
[150]蒲含林,王正濂,黄巧娟,等.双白术内酯对豚鼠离体心房肌的作用[J].中国药理学通报,2000,16(1):60-62.
[151]叶水泉.上品仙药--茯苓[J].现代养生,2004,(5):37.
[152]李玉平,李林.茯苓的临床新用途[J].职业与健康,2000,16(8):122-123.
[153]贡云华,蒋家雄.三七皂甙C1对四氧嘧啶糖尿病小鼠的降血糖作用[J].药学学报,1991,26(2):81-85.
[154]甘雨,徐惠波,孙晓波.三七总皂苷的药理作用研究进展[J].时珍国医国药,2007,18(5):1251-1252.
[155]占宏静.中药丹参药理作用新发展[J].健康大视野:医学分册,2006,14(8):77.
[156]雷载权.中药学[M].上海:上海科学技术出版社.1995:205.
[157]南京中医药大学编著.中药大辞典[M].上海:上海科学技术出版社.2006.
[158]胡烈.玉米须临床新用[J].中国临床医生,2000,28(8):40-41.
[159]郭颖,丁鹤林,傅祖植,等.糖尿病心血管并发症的药物防治[J].中国处方药,2005(6):54-57.
[160]金文胜.控制糖尿病心血管危险因素研究进展[J].继续医学教育,2005,19(1):14-17.
[161]王建华.控制血糖波动减少糖尿病慢性并发症[J].临床药物治疗杂志,2007,5(4):38-39,4.
[162]耿黎明.2型糖尿病合并冠心病患者心电图及冠脉造影结果的分析[J].临床心电学杂志,2008,17(6):429-431.
[163]陈灏珠.实用内科学·第12版[M].北京:人民卫生出版社.2006,1469.
[164]张春芳,周亚滨,陈会君,等.益气温阳、活血化瘀方对兔血管成形术后再狭窄PDGF-B mRNA表达的影响[J].中国介入影像与治疗学,2006,3(2):145-148.
[165]欧阳真理.益气温阳宣痹通络法治疗冠心病心绞痛60例[J].深圳中西医结合杂志,2006,16(1):49-49.
[166]王昃睿,王晓伟.益气温阳活血通络方治疗冠心病心绞痛101例[J].中国民间疗法,2007,15(4):19-20.
[167]周兆华,顾庆华,蒋烈,等.2型糖尿病合并冠心病患者的血脂异常分析[J].井冈山学院学报:综合版,2006;27(12):107-109.
[168]崔国敏,李振娥.糖尿病合并冠心病危险因素分析[J].济宁医学院学报,2000, 23(1):66-67.
[169]周勇,孙虹云.2型糖尿病合并冠心病的危险因素分析[J].蚌埠医学院学报,2003,28(1):31-32.
[170]郭颖,丁鹤林,傅祖植,等.糖尿病心血管并发症的药物防治[J].中国处方药,2005(6):54-57.
[171]刘国良.糖尿病诊断治疗的最新进展[J].中国实用内科杂志,2000,20(1):29-32.
[172]司徒玉,黄萍萍.肾功能不同损害期患者血清胱抑素C与血肌酐、肌酐清除率的相关性研究[J].广东医学院学报,2004,22(2):137-138.
[173]张微,张波,吕田,等.半胱氨酸蛋白酶抑制物C在心力衰竭的临床意义[J].岭南心血管病杂志,2008,14(5):338-340.
[174]马静,解汝娟.慢性肾脏病非透析患者血清半胱氨酸蛋白酶抑制剂C与心脏功能和生化指标的关系[J].中国血液净化,2008,7(4):183-187.
[175]李凯,刘伯学,蔡天志,等.半胱氨酸蛋白酶抑制剂C与左室射血分数关系的临床研究[J].实用心脑肺血管病杂志,2007,15(12):912-913.